ASH 2023: PERSEUS Trial Overview

EP: 1.Unmet Needs and Treatment Approaches in Newly Diagnosed Multiple Myeloma

Now Viewing

EP: 2.ASH 2023: PERSEUS Trial Overview

EP: 3.Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients

EP: 4.ASH 2023: Analyzing IsKia Trial

EP: 5.Examining Data from MonumenTAL-2 Study

EP: 6.Optimizing Bispecific Use in Multiple Myeloma Treatment

EP: 7.Navigating Impact of RRMM Treatment on Patient Quality of Life

EP: 8.Key RRMM-Related Takeaways from ASH 2023

This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.

The PERSEUS trial compared bortezomib, lenalidomide, and dexamethasone (VRd) to lenalidomide, bortezomib, and dexamethasone plus daratumumab (D-VRd) in over 700 newly diagnosed, transplant-eligible multiple myeloma patients. After induction, stem cell transplant, and consolidation with the same regimens, patients in the VRd arm received lenalidomide maintenance while patients in the D-VRd armreceived daratumumab plus lenalidomide. Importantly, minimal residual disease (MRD) testing occurred, allowing therapy discontinuation in sustained MRD-negative complete responders after 2 years.

At 4 years, progression-free survival was 84.3% with D-VRd vs 67.7% with VRd (HR, 0.42), a statistically significant difference. Response rates including complete response and MRD negativity also favored D-VRd. Given the strength of these phase 3 results, D-VRd should be considered for initial induction for transplant-eligible myeloma. Adding daratumumab improves outcomes, including in the maintenance setting, while generic availability makes this affordable globally.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.